Ozempic

Ozempic is a prescription medication used for managing blood sugar levels in adults with type 2 diabetes. It contains the active ingredient semaglutide and is also noted for its potential to aid in weight loss for individuals with obesity. Administered as a once-weekly injection, Ozempic works by mimicking the functions of the GLP-1 hormone, effectively increasing insulin secretion and slowing gastric emptying, which leads to reduced food intake and improved metabolic health.

CCI Score

-36.85

0.04% June 4

Latest Event

Novo Nordisk Expands Lobbying Efforts

Novo Nordisk, the maker of Ozempic, has expanded its political influence by hiring a new lobbying firm, E3 Strategic Consulting Group’s Patrick Foley, to lobby on research and funding for its products. The hiring follows a period of increased lobbying spending and comes amid tensions with progressive lawmakers, such as the noted feud involving Senate HELP Chair Bernie Sanders.

Take Action

So what can you do? It's time to make tough choices. Where will you cast your vote?

Shop Alternatives SEE ALL: Argenx

Verona Pharma

Novo Nordisk
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

TOADIE

Ozempic is currently rated as a Toadie.

-30 to -44 CCI Score

Companies scoring in this range actively seek to please authoritarian regimes. They offer proactive support and assistance in exchange for preferential treatment, compromising ethical standards for business gains and political favor.

Latest Events

AUG

09

2024

Novo Nordisk Expands Lobbying Efforts
-36.85

Novo Nordisk, the maker of Ozempic, has expanded its political influence by hiring a new lobbying firm, E3 Strategic Consulting Group’s Patrick Foley, to lobby on research and funding for its products. The hiring follows a period of increased lobbying spending and comes amid tensions with progressive lawmakers, such as the noted feud involving Senate HELP Chair Bernie Sanders.
-40

Political Contributions and Lobbying Efforts

May 13

The hiring of a new lobbying firm indicates that Novo Nordisk is intensifying its efforts to shape public policy and secure favorable legislative outcomes. Such heightened corporate political activity can undermine democratic processes and marginalize progressive, anti-fascist policy approaches, marking a negative development in terms of corporate complicity in authoritarian influence.

Ozempic maker, vape trade group add lobbyists
AUG

09

2024

Novo Nordisk’s New Lobbying Hire
-36.85

Novo Nordisk, the maker of Ozempic, has recently retained E3 Strategic Consulting Group's Patrick Foley to lobby on research and funding for its weight loss drugs. This move, disclosed in recent filings, marks a continued and significant engagement in political lobbying efforts.
-40

Political Contributions and Lobbying Efforts

May 13

The hiring of a new lobbying firm by the maker of Ozempic highlights the company’s active engagement in shaping policy in favor of its commercial interests. Such political lobbying contributes to corporate influence on public policy, which can undermine democratic accountability.

Ozempic maker, vape trade group add lobbyists